Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review | Zendy

ChihJen Yang | Zendy; Yu-Jui Wei | Zendy; Hsu-Liang Chang | Zendy; Pi-Yu Chang | Zendy; Chung-Chen Tsai | Zendy; YenHsu Chen | Zendy; PoRen Hsueh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review

Author(s) -

ChihJen Yang,

Yu-Jui Wei,

Hsu-Liang Chang,

Pi-Yu Chang,

Chung-Chen Tsai,

YenHsu Chen,

PoRen Hsueh

Publication year - 2020

Publication title -

journal of microbiology immunology and infection

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.223

H-Index - 57

eISSN - 1995-9133

pISSN - 1684-1182

DOI - 10.1016/j.jmii.2020.09.002

Subject(s) - pandemic , medicine , coronavirus , covid-19 , pneumonia , disease , viral pneumonia , betacoronavirus , intensive care medicine , virology , clinical trial , immunology , outbreak , infectious disease (medical specialty)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative viral pathogen of coronavirus disease 2019 (COVID-19), appears to have various clinical presentations and may result in severe respiratory failure. The global SARS-CoV-2-associated viral pneumonia pandemic was first reported in December 2019 in China. Based on known pharmacological mechanisms, many therapeutic drugs have been repurposed to target SARS-CoV-2. Among these drugs, remdesivir appears to be the currently most promising according to several clinical trials and reports of compassionate use. In this mini-review, we summarize the current evidence on the efficacy and challenges of remdesivir for the treatment of coronavirus disease 2019 (COVID-19).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research